Ganseerpel
Advisory Board, Senior Moderator
One ofthe most critical issues in vaccine design is the choice of the adiuvant.
Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com
fficeffice" /><o
></o>
<o></o>
Journal of Virology, March 2005, p. 2910-2919, Vol. 79, No. 5<o></o>
0022-538X/05/$08.00+0 doi:10.1128/JVI.79.5.2910-2919.2005<o></o>
Takeshi Ichinohe,1,2 Izumi Watanabe,1,2 Satoshi Ito,1,2 Hideki Fujii,3 Masami Moriyama,4 Shin-ichi Tamura,5 Hidehiro Takahashi,1 Hirofumi Sawa,6 Joe Chiba,2 Takeshi Kurata,1 Tetsutaro Sata,1 and Hideki Hasegawa1* <o></o>
<o></o>
Department of Pathology, National Institute of Infectious Diseases, Musashimurayama-shi,1 Department of Immunology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku,3 Department of Microbiology and Immunology, School of Medicine, Keio University, Shinano-machi, Shinjyuku-ku, Tokyo,4 Department of Biological Science and Technology, Tokyo University of Science, Yamazaki, Noda, Chiba,2 Laboratory of Prevention of Viral Diseases, Research Institute for Microbial Diseases, Osaka University, Yamadaoka, Suita, Osaka,5 Laboratory of Molecular & Cellular Pathology, 21st Century COE, Program for Zoonosis Control, Hokkaido University School of Medicine, and CREST, JST, Kita-ku, Sapporo, Japan6<o></o>
<o></o>
full text:<o></o>
http://jvi.asm.org/cgi/content/full/79/5/2910?view=long&pmid=15709010<o></o>
<o></o>
The mucosal adjuvant effect of synthetic double-stranded RNA polyriboinosinic polyribocytidylic acid [poly(I:C)] against influenza virus was examined under intranasal coadministration with inactivated hemagglutinin (HA) vaccine in BALB/c mice and was shown to have a protective effect against both nasal-restricted infection and lethal lung infection. Intranasal administration of vaccine from PR8 (H1N1) with poly(I:C) induced a high anti-HA immunoglobulin A (IgA) response in the nasal wash and IgG antibody response in the serum, while vaccination without poly(I:C) induced little response. Intracerebral injection confirmed the safety of poly(I:C). In addition, we demonstrated that administration of poly(I:C) with either A/Beijing (H1N1) or A/Yamagata (H1N1) vaccine conferred complete protection against PR8 challenge in this mouse nasal infection model, suggesting that poly(I:C) possessed cross-protection ability against variant viruses. To investigate the mechanism of the protective effect of poly(I:C), mRNA levels of Toll-like receptors and cytokines were examined in the nasal-associated lymphoid tissue after vaccination or virus challenge. Intranasal administration of HA vaccine with poly(I:C) up-regulated expression of Toll-like receptor 3 and alpha/beta interferons as well as Th1- and Th2-related cytokines. We propose that poly(I:C) is a new effective intranasal adjuvant for influenza virus vaccine.<o></o>
<o></o>
Synthetic Double-Stranded RNA Poly(I:C) Combined with Mucosal Vaccine Protects against Influenza Virus Infection <?xml:namespace prefix = o ns = "urn:schemas-microsoft-com
fficeffice" /><o></o><o
></o>Journal of Virology, March 2005, p. 2910-2919, Vol. 79, No. 5<o
></o>0022-538X/05/$08.00+0 doi:10.1128/JVI.79.5.2910-2919.2005<o
></o>Takeshi Ichinohe,1,2 Izumi Watanabe,1,2 Satoshi Ito,1,2 Hideki Fujii,3 Masami Moriyama,4 Shin-ichi Tamura,5 Hidehiro Takahashi,1 Hirofumi Sawa,6 Joe Chiba,2 Takeshi Kurata,1 Tetsutaro Sata,1 and Hideki Hasegawa1* <o
></o><o
></o>Department of Pathology, National Institute of Infectious Diseases, Musashimurayama-shi,1 Department of Immunology, National Institute of Infectious Diseases, Toyama, Shinjuku-ku,3 Department of Microbiology and Immunology, School of Medicine, Keio University, Shinano-machi, Shinjyuku-ku, Tokyo,4 Department of Biological Science and Technology, Tokyo University of Science, Yamazaki, Noda, Chiba,2 Laboratory of Prevention of Viral Diseases, Research Institute for Microbial Diseases, Osaka University, Yamadaoka, Suita, Osaka,5 Laboratory of Molecular & Cellular Pathology, 21st Century COE, Program for Zoonosis Control, Hokkaido University School of Medicine, and CREST, JST, Kita-ku, Sapporo, Japan6<o
></o><o
></o>full text:<o
></o>http://jvi.asm.org/cgi/content/full/79/5/2910?view=long&pmid=15709010<o
></o><o
></o>The mucosal adjuvant effect of synthetic double-stranded RNA polyriboinosinic polyribocytidylic acid [poly(I:C)] against influenza virus was examined under intranasal coadministration with inactivated hemagglutinin (HA) vaccine in BALB/c mice and was shown to have a protective effect against both nasal-restricted infection and lethal lung infection. Intranasal administration of vaccine from PR8 (H1N1) with poly(I:C) induced a high anti-HA immunoglobulin A (IgA) response in the nasal wash and IgG antibody response in the serum, while vaccination without poly(I:C) induced little response. Intracerebral injection confirmed the safety of poly(I:C). In addition, we demonstrated that administration of poly(I:C) with either A/Beijing (H1N1) or A/Yamagata (H1N1) vaccine conferred complete protection against PR8 challenge in this mouse nasal infection model, suggesting that poly(I:C) possessed cross-protection ability against variant viruses. To investigate the mechanism of the protective effect of poly(I:C), mRNA levels of Toll-like receptors and cytokines were examined in the nasal-associated lymphoid tissue after vaccination or virus challenge. Intranasal administration of HA vaccine with poly(I:C) up-regulated expression of Toll-like receptor 3 and alpha/beta interferons as well as Th1- and Th2-related cytokines. We propose that poly(I:C) is a new effective intranasal adjuvant for influenza virus vaccine.<o
></o><o
></o>